HomeCompareCEBUY vs ABBV

CEBUY vs ABBV: Dividend Comparison 2026

CEBUY yields 78.74% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CEBUY wins by $1.47M in total portfolio value
10 years
CEBUY
CEBUY
● Live price
78.74%
Share price
$2.54
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.57M
Annual income
$448,281.13
Full CEBUY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CEBUY vs ABBV

📍 CEBUY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCEBUYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CEBUY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CEBUY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CEBUY
Annual income on $10K today (after 15% tax)
$6,692.91/yr
After 10yr DRIP, annual income (after tax)
$381,038.96/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CEBUY beats the other by $359,982.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CEBUY + ABBV for your $10,000?

CEBUY: 50%ABBV: 50%
100% ABBV50/50100% CEBUY
Portfolio after 10yr
$835.3K
Annual income
$236,526.45/yr
Blended yield
28.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CEBUY
No analyst data
Altman Z
0.6
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CEBUY buys
0
ABBV buys
0
No recent congressional trades found for CEBUY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCEBUYABBV
Forward yield78.74%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$1.57M$102.3K
Annual income after 10y$448,281.13$24,771.77
Total dividends collected$1.36M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CEBUY vs ABBV ($10,000, DRIP)

YearCEBUY PortfolioCEBUY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$18,574$7,874.02$11,550$430.00+$7.0KCEBUY
2$33,543$13,668.42$13,472$627.96+$20.1KCEBUY
3$58,959$23,068.84$15,906$926.08+$43.1KCEBUY
4$100,983$37,896.43$19,071$1,382.55+$81.9KCEBUY
5$168,713$60,661.00$23,302$2,095.81+$145.4KCEBUY
6$275,239$94,716.47$29,150$3,237.93+$246.1KCEBUY
7$438,918$144,412.20$37,536$5,121.41+$401.4KCEBUY
8$684,868$215,225.32$50,079$8,338.38+$634.8KCEBUY
9$1,046,666$313,857.68$69,753$14,065.80+$976.9KCEBUY
10$1,568,214$448,281.13$102,337$24,771.77+$1.47MCEBUY

CEBUY vs ABBV: Complete Analysis 2026

CEBUYStock

Cebu Air, Inc., an airline, provides international and domestic air transportation services. It offers scheduled air travel services to passengers, as well as airport-to-airport cargo services on its domestic and international routes. The company also provides ancillary services, such as cancellation and rebooking options; in-flight merchandising, including sale of duty-free products on international flights; baggage services; and travel-related products and services. As of December 31, 2021, it operated a fleet of 74 aircraft, including 22 Airbus A320 CEO, 7 Airbus A321 CEO, 6 Airbus A320 NEO, 9 Airbus A321 NEO, 6 Airbus A330 CEO, 2 Airbus A330 NEO, 8 ATR 72-500, and 14 ATR 72-600. The company was incorporated in 1988 and is headquartered in Pasay City, the Philippines. Cebu Air, Inc. is a subsidiary of CP Air Holdings, Inc.

Full CEBUY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CEBUY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CEBUY vs SCHDCEBUY vs JEPICEBUY vs OCEBUY vs KOCEBUY vs MAINCEBUY vs JNJCEBUY vs MRKCEBUY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.